We are committed to improving the health of people worldwide. Therefore, we strive to discover, develop and deliver innovative medicines. One of our greatest assets in achieving this mission are our people that are translating science into survival โ our scientists optimize and expand our therapeutic toolbox, our manufacturing experts enable the scale-up and establishment of innovative production sites around the globe, our regulatory and commercial teams lead our efforts of bringing our medicines to people globally as well as our corporate governance, operations and legal leaders that ensure the smooth running of our organization.
Together, we are working diligently to usher in a new era in immunotherapy to help address medical needs. Pedro L. Alonso, M. The vision of the GHO is to achieve impact and promote health equity. He has helped develop improved diagnostic, treatment, and prevention strategies, including vaccines. Additionally, he has overseen more than 20 Ph. National Academy of Medicine. Her responsibilities included leading HR across multiple regions, managing global learning and development programs, and driving human resources strategy and operations.
She started her career at Accenture as a Management Consultant. Having joined BioNTech in , the year in which BioNTech went public, Lisa has since played a key role in building, expanding and professionalizing the finance organization. Lisa continues to focus on streamlining and automating financial processes to scale the performance of the organization.
Prior to joining BioNTech, she gained extensive experience in the audit and finance sector. Constanze Blume, Ph. She joined the company in to provide regulatory support to its growing oncology pipeline and to build the Regulatory Affairs department which she co-leads with Ruben Rizzi. Further, she is responsible for the regulatory aspects of artworks for commercial products, regulatory policy, and regulatory intelligence. She co-led the regulatory team defining and executing the global regulatory strategy, focusing on registrational CMC aspects and, in the later stages of clinical development, on the commercial artworks, thus securing regulatory approvals for the vaccine and for subsequent variant-adapted versions as well as the expansion of the EU-relevant manufacturing network.
She therefore has contributed heavily to the success of the collaboration with Pfizer, while establishing trust-based exchanges with global regulators.
